Abingworth LLP Verona Pharma PLC Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
A detailed history of Abingworth LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Abingworth LLP holds 2,457,500 shares of VRNA stock, worth $114 Million. This represents 21.3% of its overall portfolio holdings.
Number of Shares
2,457,500
Previous 2,457,500
-0.0%
Holding current value
$114 Million
Previous $25.1 Million
155.92%
% of portfolio
21.3%
Previous 8.58%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
167Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$292 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$258 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$231 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$195 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$164 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $2.82B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...